NCT07021326Completed
Phase Angle and TyG Index as Markers of Glycaemic Control, Adiposity and Cardiovascular Risk in T1D Adolescents
Phase Angle and Triglyceride-glucose Index as Glycaemic Control, Body Composition and Cardiovascular Risk Biomarkers in Adolescents With Type 1 Diabetes: a Cross-sectional Study.
Source: ClinicalTrials.gov · Last updated 13 Jun 2025
Brief summary (registry, in English)
This study aimed to identify new clinical biomarkers that may improve the follow-up and health outcomes of adolescents with type 1 diabetes. The current clinical practice includes a standard set of measurements for monitoring glycemic control and general health. However, other parameters such as phase angle (obtained through a fast, simple, and painless body composition analysis) might also provide valuable insight into the metabolic status of these patients. This is a cross-sectional observational study that involved a one-time data collection process. Participants underwent a single body composition measurement (10 seconds, using a bioimpedance analyzer). No interventions or follow-up visits were required. Additional data was extracted from medical records, including clinical information (e.g., age of diabetes onset, HbA1c, anthropometrics) and results from recent blood tests. The goal is to determine whether indicators such as the phase angle and triglyceride-glucose (TyG) index could serve as non-invasive tools to assess glycemic control, glycaemic control and cardiovascular risk in adolescents with type 1 diabetes. The study was conducted at two hospitals from Alicante (Spain) and included patients with a confirmed diagnosis of type 1 diabetes who met the inclusion criteria. Participation was entirely voluntary with informed consent obtained from legal guardians. All collected data were anonymized to prevent reidentification and unauthorized access. This research seeks to expand scientific knowledge on diabetes management and support the development of more precise, individualized monitoring tools for young people living with type 1 diabetes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 73 (actual)
- First submitted
- 25 May 2025
- Start date
- 21 Jul 2022
- Primary completion date
- 22 Oct 2024
- Lead sponsor
- University of Alicante
- Diseases
- Type 1 diabetes
- NCT number
- NCT07021326
What you commit to
- Study type: Observational
- Participants enrolled: 73
- From 21 Jul 2022 to the primary completion date, 22 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not being hospitalized.
- Not being pregnant, in the case of female patients.
Who the study is looking for
- Patients with type 1 diabetes mellitus (diagnosed).
- Aged between 10 and 20 years.
- With or without a continuous glucose monitor.
Age in the registry: 10 years to 19 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital General Universitario de Elche Coordinator of this site? Confirm its status | Elche | Spain | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.